Cantor Fitzgerald has reiterated an Overweight rating on PTC Therapeutics and reaffirmed a $124.00 price target after the company released its fourth-quarter 2025 results. That price target corresponds to the upper bound of Wall Street projections, where analyst targets span from $60 to $124.
PTC reported its fourth-quarter 2025 earnings on Wednesday, following a revenue preannouncement for the full year made last month. The quarter included the first full-period contribution from Sephience, PTC's treatment for phenylketonuria (PKU), which posted Sephience sales of $92 million for the quarter. That number beat investor expectations by roughly $30 million, according to the company disclosures.
For the trailing twelve months, total revenue jumped 97.5% to $1.78 billion, based on InvestingPro data cited by the company. In the wider 2025 results, PTC disclosed fourth-quarter global Sephience revenue of $92.5 million and reported total product and royalty revenue of approximately $823.4 million for the year, exceeding its prior guidance. Product revenue alone was about $587.8 million for 2025.
Cantor Fitzgerald highlighted a modeling issue that may affect sell-side 2026 revenue assumptions. Specifically, some analysts’ projections appear not to incorporate the removal of Evrysdi royalties from PTC's books; the company sold the remaining portion of those royalties last year. The firm also noted that the company’s 2026 guidance looks lower relative to aggregated analyst estimates, a dynamic that has contributed to share price volatility since the revenue preannouncement last month.
At the time referenced in the report, the stock was trading at $67.24 with a price-to-earnings ratio of 7.32. InvestingPro analysis included in the coverage suggests the shares are trading below the platform’s Fair Value estimate.
PTC also reported a regulatory milestone during the period: the Japanese Ministry of Health, Labor and Welfare approved Sephience, marking the company’s first product approval in Japan. On the development front, PTC recently withdrew its New Drug Application resubmission for Translarna after receiving feedback from the U.S. Food and Drug Administration indicating the resubmission was unlikely to meet the required threshold for approval.
In addition to Cantor Fitzgerald’s position, other broker activity accompanied the report. Barclays initiated coverage of PTC with an Overweight rating, citing a view that Sephience could reach more than $2 billion in peak annual sales. Conversely, Goldman Sachs raised its price target to $55 from $50 while maintaining a Sell rating.
The company has provided 2026 guidance that, as Cantor Fitzgerald observed, appears conservative versus consensus. The interaction between that guidance and the structural change from the Evrysdi royalty sale is a focal point for revenue modeling in coming quarters.
For investors seeking further quantitative and qualitative analysis, a Pro Research Report is available that covers PTC Therapeutics alongside more than 1,400 other U.S. equities.
Context for market participants - The combination of an early commercial beat from Sephience, a material jump in year-over-year revenue, and ongoing changes to royalty streams informs differing analyst opinions on near-term valuation and longer-term upside potential. The juxtaposition of high-end price targets from some brokers and negative or cautious stances from others underlines the range of outcomes being considered by the sell side.